Generic Name and Formulations:
Tazarotene 0.1%; crm.
Indications for AVAGE:
Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of facial fine wrinkles, facial mottled hyper- and hypopigmentation, and facial benign lentigines.
Limitations Of use:
Does not eliminate or prevent wrinkles or restore more youthful skin. Does not reverse photoaging or repair sun damaged skin; does not mitigate coarse or deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. The safety and effectiveness for the prevention or treatment of actinic keratoses, skin neoplasms, or lentigo maligna have not been established.
≥17yrs: apply thin film to entire face once daily in the PM. Females of reproductive potential: begin therapy during normal menses.
<17yrs: not established.
Assess any facial pigmented lesions (eg, lentigo maligna) prior to initiation. Obtain reliable negative pregnancy test within 2 weeks prior to therapy. Females of reproductive potential should use effective contraception. Do not use on broken, eczematous, or sunburned skin. Sun sensitivity. Avoid eyes, mouth, sun, and UV light. Increased irritation in extreme weather. Discontinue or reduce dose frequency if excessive irritation occurs. Nursing mothers.
Avoid use until the effects of strong drying agents have subsided. Avoid concomitant with photosensitizers or other irritants.
Desquamation, erythema, burning, dry or irritation skin, pruritus, irritant contact dermatitis, stinging, rash, cheilitis.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States